Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience

Figures & data

Figure 1. Impact of the treatment with tralokinumab on subjective symptoms and patients’ quality of life: achievement of pp-NRS and s-NRS reduction ≥ 4 points (a) and ADCT ≤ 7 (c) at week 16. Decrease in median pp-NRS and s-NRS (b) and median ADCT (d) after 16 weeks. pp-NRS: Peak Pruritus- Numerical Rating Scale; s-NRS: Sleep-Numerical Rating Scale; ADCT: Atopic Dermatitis Control Tool.

Figure 2. Clinical improvement after 16 weeks of treatment with tralokinumab: decrease in median EASI (a); percentages of patients achieving EASI 50 and EASI 75 (b), and proportion of patients reaching an IGA of 0 or 1 (c) at week 16. EASI: Eczema Area and Severity Index; IGA: Investigator’s Global Assessment.

Table 1. Demographic and clinical characteristics of our patients at baseline.

Characteristics
Age (years), median (IQR)	32.5 (23.75)
Female sex, n (%)	7 (70)
Adult-onset (≥20 years), n (%)	4 (40)
BMI, median (IQR)	21.70 (6.44)
Previous dupilumab, n (%)	5 (50)
Atopic comorbidities, n (%)	6 (60)
Allergic asthma, n (%)	2 (20)
Allergic rhinitis, n (%)	3 (30)
Allergic conjunctivitis, n (%)	1 (10)
EASI baseline, median (IQR)	20 (8)
pp-NRS, median (IQR)	9 (1.5)
s-NRS, median (IQR)	7 (1.1)
ADCT baseline, median (IQR)	16 (2.75)
IGA ≥3, n (%)	10 (100)

Note: IQR: interquartile range; BMI: body mass index; EASI: Eczema Area and Severity Index; pp-NRS: Peak Pruritus-Numerical Rating Scale; s-NRS: Sleep-Numerical Rating Scale; ADCT: Atopic Dermatitis Control Tool; IGA: Investigator’s Global Assessment.

Data availability statement

Additional data supporting the findings of this manuscript are available on reasonable request to the corresponding author.